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ABSTRACT 
Ultra performance liquid chromatography method was developed for the simultaneous estimation of the Artemether (AMT) and Lumefantrine 
(LFT) in Tablet dosage form. Chromatogram was run through X-bridge C18 100 x 2.1 mm, 3.5. Mobile phase containing Buffer 0.01N KH2PO4 
(3.5pH): Acetonitrile taken in the ratio 55:45 was pumped through column at a flow rate of 0.3ml/min. Buffer used in this method was 0.01N 
KH2PO4. Temperature was maintained at 30°C. Optimized wavelength selected was 215nm. Retention time of AMT and LFT were found to be 
0.787 min and 1.572min. %RSD of the AMT and LFT were and found to be 0.7 and 0.6 respectively. %Recovery was obtained as 99.49% and 
100.22% for AMT and LFT respectively. LOD, LOQ values obtained from regression equations of AMT and LFT were 0.03, 0.08 and 0.095, 0.288 
respectively. Regression equation of AMT is y = 19308x + 1509 and y = 36919x + 11566 of LFT. The developed method was simple and 
economical that can be adopted in regular Quality control test in Industries. 
Keywords: Artemether (AMT), Lumefantrine (LFT), Acetonitrile, UPLC. 
 
Article Info: Received 31 Jan 2019;     Review Completed 04 March 2019;     Accepted 09 March 2019;     Available online 15 March 2019 
Cite this article as: 
Sukanya B, Mohan Goud V, Anitha P, Stability indicating Ultra Performance Liquid Chromatography method development 
and validation for simultaneous estimation of artemether and lumefantrine in bulk and pharmaceutical dosage form, 
Journal of Drug Delivery and Therapeutics. 2019; 9(2):217-221     http://dx.doi.org/10.22270/jddt.v9i2.2408                                                         
*Address for Correspondence:  
Sukanya Bandari, Department of Pharmaceutical Analysis, Joginpally B. R Pharmacy College, Yenkapally, Moinabad, R.R. Dist. Telangana 
 
 
INTRODUCTION 
AMT 1, 2 is an antimalarial agent used to treat acute 
uncomplicated malaria. Chemical name of AMT is 3,12-
Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-
methoxy-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,10S,12R,12aR). 
It is administered in combination with LFT for improved 
efficacy. This combination therapy exerts its effects against 
the erythrocytic stages of Plasmodium spp. and may be used 
to treat infections caused by P. falciparum and unidentified 
Plasmodium species, including infections acquired in 
chloroquine-resistant areas 3. 
LFT is an antimalarial agent used to treat acute 
uncomplicated malaria. Chemical name of LFT 2-
(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl) 
methylidene] -9H-fluoren-4-yl] ethan-1-ol. It is administered 
in combination with AMT for improved efficacy. This 
combination therapy exerts its effects against the 
erythrocytic stages of Plasmodium spp. and may be used to 
treat infections caused by P. falciparum and unidentified 
Plasmodium species, including infections acquired in 
chloroquine-resistant areas 4. 
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Figure.1: Structures for AMT and LFT 
Literature review 7- 19 reveals that different methods RP-
HPLC, UV, LCMS for its analysis in formulations. Hence our 
present plan is to develop a new, sensitive, robust& accurate 
method for its analysis in formulation, after a detailed study, 
a new UPLC method was decided to be developed and 
validated as per ICH norms5, 6. 
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MATERIALS AND METHODS 
Instruments Used: 
Electronics Balance-Denver, pH meter -BVK enterprises, 
India, Ultra sonicator-BVK enterprises, WATERS UPLC 2695 
SYSTEM equipped with quaternary pumps, Photo Diode 
Array detector and Auto sampler integrated with Empower 2 
Software. UV-VIS spectrophotometer PG Instruments T60 
with special bandwidth of 2 mm and 10mm and matched 
quartz cells integrated with UV win 6 Software was used for 
measuring absorbances of AMT and LFT solutions. 
Drug samples: 
AMT 20mg and LFT 120mg. 
Reagents and Solutions: 
Distilled water, Acetonitrile, Phosphate buffer, Methanol, 
Ortho-phosphoric acid [All are HPLC grade], Potassium 
dehydrogenate ortho phosphate buffer [AR]. 
Analytical methodology: 
Diluent: Based up on the solubility of the drugs, diluent was 
selected, Acetonitrile and Water taken in the ratio of 50:50. 
Preparation of Standard stock solutions: Accurately 
weighed 5 mg of AMT, 30 mg of LFT and transferred to 
individual 25 ml volumetric flasks separately. 3/4th of 
diluents was added to both of these flasks and sonicated for 
10 minutes. Flasks were made up with diluents and labeled 
as Standard stock solution 1and 2. (200µg/ml of AMT and 
1200µg/ml of LFT). 
Preparation of Standard working solutions (100% 
solution): 1ml from each stock solution was pipetted out 
and taken into a 10ml volumetric flask and made up with 
diluent. (20µg/ml AMT of and 120µg/ml of LFT). 
Preparation of Sample stock solutions: 5 tablets were 
weighed and the average weight of each tablet was 
calculated, then the weight equivalent to 1 tablet was 
transferred into a 50 ml volumetric flask, 25ml of diluents 
was added and sonicated for 25 min, further the volume was 
made up with diluent and filtered by HPLC filters (400µg/ml 
of AMT and 2400µg/ml of LFT). 
Preparation of Sample working solutions (100% 
solution): 0.5ml of filtered sample stock solution was 
transferred to 10ml volumetric flask and made up with 
diluent. (20µg/ml of AMT and 120µg/ml of LFT). 
Preparation of buffer: 
0.1% OPA Buffer: 1ml of Conc. Ortho Phosphoric acid was 
diluted to 1000ml with water.  
Mobile phase: Mobile phases used for HPLC are typically 
mixtures of organic solvents and water or aqueous buffers. 
RESULTS AND DISCUSSION 
Method Development 
Optimized method: Trials were performed for the method 
development and the best peak with least fronting factor was 
found to be with RT=0.783 min for AMT and 1.573min for 
LFT.
 
Table 1: Chromatographic conditions 
Mobile phase 55% 0.01N KH2PO4 buffer: 45% Acetonitrile 
Flow rate 1ml/min  
Column X-bridge C18 (4.6 x 100mm, 5µm) 
Detector wavelength 215nm 
Column temperature 30°C  
Injection volume 0.5L  
Run time 3.0 min 
Diluent Water and Acetonitrile in the ratio 50:50 
Results  Both peaks have good resolution, tailing factor, theoretical plate count and resolution. 
 
 
Figure 2: System suitability chromatogram 
 
System Suitability: According to ICH guidelines plate count 
should be more than 2000, tailing factor should be less than 
2 and resolution must be more than 2. All the system suitable 
parameters were passed and were within the limits. 
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Table 2: System suitability parameters for AMT and LFT 
S. No  AMT LFT 
Injection RT (min) USP Plate Count Tailing RT (min) USP Plate 
Count 
Tailing Resolution 
1 0.786 2017 1.45 1.568 3312 1.33 7.4 
2 0.786 2013 1.47 1.568 3520 1.39 7.3 
3 0.786 2962 1.47 1.570 3479 1.37 7.4 
4 0.787 2041 1.47 1.570 3349 1.41 7.0 
5 0.787 2934 1.59 1.570 2798 1.42 6.8 
6 0.788 2837 1.62 1.572 2834 1.42 6.8 
 
Methods for Validation 
Linearity: Six linear concentrations of AMT (5-30µg/ml) and 
LFT (30-180µg/ml) were injected in a duplicate manner. 
Average areas were mentioned above and linearity 
equations obtained for AMT was y = 19308x + 1509.4 and of 
LFT was y = 36919x + 115664 Correlation coefficient 
obtained was 0.999 for the two drugs. 
 
 
Table 3: Linearity table for AMT and LFT 
AMT LFT 
Conc (μg/mL) Peak area Conc (μg/mL) Peak area 
0 0 0 0 
5 102290 30 1269437 
10 200320 60 2442112 
15 279892 90 3439710 
20 385202 120 4553166 
25 487724 150 5653184 
30 582440 180 6711237 
 
 
Figure 3: Calibration curve of AMT 
 
Figure 4: Calibration curve of LFT
 
Precision: From a single volumetric flask of working 
standard solution six injections were given and the obtained 
areas were mentioned above. Average area, standard 
deviation and % RSD were calculated for two drugs. % RSD 
obtained as 0.3% and 0.3% respectively for AMT and LFT. As 
the limit of Precision was less than “2” the system precision 
was passed in this method. 
 
Table 4: System precision table of AMT and LFT 
S. No Area of AMT 
Day-Day precision 
Peak area 
Area of LFT 
Day-Day precision 
Peak area 
1.  380088 374570 4595070 4590553 
2.  380169 371816 4585652 4515867 
3.  378427 374545 4591200 4506563 
4.  380085 377682 4586047 4596058 
5.  380944 376553 4611663 4538194 
6.  381169 370952 4610550 4545747 
Mean  380147 374353 4596697 4548830 
S.D  964.0 2608.0 11697.6 37328.2 
%RSD  0.3 0.7 0.3 0.8 
 
y = 19308x + 1509.4 
R² = 0.9992 
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Accuracy: Three levels of Accuracy samples were prepared 
by standard addition method. Triplicate injections were 
given for each level of accuracy and mean %Recovery was 
obtained as 99.49% and 98.71% for AMT and LFT 
respectively.
 
Table 5: Recovery studies for AMT and LFT 
%Concentration 
AMT LFT 
50% 100% 150% 50% 100% 150% 
Trail-I 96.88 96.88 99.66 100.53 100.10 99.90 
Trail-II 98.71 98.71 99.80 99.26 98.97 98.71 
Trail-III 99.20 99.20 100.54 101.35 101.56 101.64 
AVG (%Recovery) 98.3 100.2 100.00 100.38 100.21 100.08 
SD 1.22 1.13 0.47 1.051 1.2990 1.4752 
%RSD 1.24 1.13 0.47 1.05 1.30 1.47 
 
Robustness: Robustness conditions like Flow minus 
(0.9ml/min), Flow plus (1.1ml/min), mobile phase minus 
(55B:45A), mobile phase plus (45B:55A), temperature minus 
(25°C) and temperature plus (35°C) was maintained and 
samples were injected in duplicate manner. System 
suitability parameters were not much affected and all the 
parameters were passed. %RSD was within the limit. 
 
 
Table 6: Robustness data for AMT and LFT 
S. No. Condition %RSD of AMT %RSD of LFT 
1 Flow rate (-) 0.9ml/min 0.6 0.6 
2 Flow rate (+) 1.1ml/min 1.7 1.6 
3 Mobile phase (-) 55B:45A 0.5 0.1 
4 Mobile phase (+) 45B:55A 1.1 0.2 
5 Temperature (-) 25°C 0.1 0.3 
6 Temperature (+) 35°C 0.9 0.3 
 
LOD and LOQ: LOD and LOQ were estimated from the signal-to-noise ratio. The LOD for AMT and LFT were found to be 0.03 and 
0.08μg/ml and the LOQ were 0.095 and 0.0288μg/ml respectively. 
Table 7: LOD AND LOQ of AMT and LFT 
Molecule LOD LOQ 
AMT 0.03 0.08 
Lumefantrine 0.095 0.288 
 
Degradation data: Degradation studies were performed 
with the formulation and the degraded samples were 
injected. Assay of the injected samples was calculated and all 
the samples passed the limits of degradation. 
 
Table 8: Degradation data of AMT and LFT 
Type of 
degradation  
  AMT LFT 
AREA %RECOVERED % DEGRADED AREA %RECOVERED % DEGRADED 
Acids 356108 93.30 6.70     4377916 95.05 4.95 
Base 365252 95.70 4.30 4338107 94.19 5.81 
Peroxide 370534 97.08 2.92 4339047 94.21 5.79 
Thermal 371099 97.23 2.77 4469922 97.05 2.95 
Uv 375429 98.36 1.64 4479189 97.25 2.75 
Water 379345 98.36 1.64 4550018 98.79 1.21 
 
 
CONCLUSION 
The UPLC method was developed and validated. The 
developed method was system suitability, precision, 
accuracy, limit of detection and limit of quantization and 
degradation studies of the simultaneous estimation of AMT 
and LFT in bulk and pharmaceutical dosage form. The 
combination of these drugs is easy to administer and may 
improve adherence in the treatment of uncomplicated 
malaria caused by plasmodium falciparum. UPLC gives 
increased resolution, speed and sensitivity for 
liquid chromatography therefore due to UPLC new chemistry 
and instrumentation technology can provide more 
information per unit of work. UPLC has main advantage over 
others is reduction of analysis time which also helps to 
reduce solvent consumption. A negative aspect of UPLC 
could be the higher back pressure than in conventional 
HPLC. This back pressure can be reduced by increasing the 
column temperature. But it seems that UPLC can offer 
significant improvements in speed, sensitivity and resolution 
compared with conventional HPLC. 
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